Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co. (Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States.
As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory. The collaboration reflects both companies' shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies.
Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs).
As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory.
Achin Gupta, managing director & global chief executive officer, Cipla, said, “This partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio.
By combining Qilu’s development strengths with Cipla’s commercial presence and patient-centric legacy, we aim to expand access to high-quality biologics for patients across our focus markets.'
Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets.
The company’s consolidated net profit declined 39.19% to Rs 789.05 crore in Q1 FY27, compared with Rs 1,297.62 crore posted in Q1 FY26. Revenue from operations increased 3.51% YoY to Rs 7,077.02 crore in the quarter ended 30th June 2026.
The scrip shed 0.58% to currently trade at Rs 1380.90 on the BSE.
Under this agreement, Cipla will receive exclusive rights to develop and commercialise Rolditamig Deuderuxtecan, also known as TQB2102, in India, South Africa and 5 other emerging markets.
Cipla will be responsible for local clinical development, regulatory activities, and commercialisation in the licensed territories, while CTTQ will continue to manufacture and supply TQB2102.
Chia Tai Tianqing Pharmaceutical Group Co. is a subsidiary of Sino Biopharmaceutical (SBP Group).
TQB2102 is being evaluated across HER2-expressing cancers and has demonstrated encouraging clinical potential in HER2-low advanced breast cancer.
The collaboration brings together SBP Group’s differentiated late-stage oncology asset and development and manufacturing capabilities with Cipla’s established regulatory, medical, market access and commercial presence across India, South Africa, and other emerging markets.
The partnership is intended to accelerate local development and regulatory approvals, enabling patient access across licensed countries, subject to applicable approvals.
Achin Gupta, managing director and global chief executive officer, Cipla said: 'Breast cancer remains a significant healthcare challenge, and this agreement strengthens our oncology portfolio with a promising HER2-targeted antibody-drug conjugate.
Through our partnership with SBP Group and CTTQ, we aim to accelerate development and, subject to regulatory approvals, expand access to this innovative treatment across licensed territories.'
The scrip shed 0.10% to currently trade at Rs 1414.60 on the BSE.
Cipla and Sino Biopharmaceutical (HKEX: 1177) (SBP Group) today announced that SBP Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co. (CTTQ), has entered into an exclusive license and supply agreement with Cipla for Rolditamig Deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC).
Under this agreement, Cipla will receive exclusive rights to develop and commercialise TQB2102 in India, South Africa and 5 other emerging markets.
The collaboration brings together SBP Group's differentiated late-stage oncology asset and development and manufacturing capabilities with Cipla's established regulatory, medical, market access and commercial presence across India, South Africa, and other emerging markets.
Profit before tax (PBT) fell 38.87% YoY to Rs 1,081.93 crore in Q1 FY27.
EBITDA stood at Rs 1,192 crore, down 32.96% compared with Rs 1,778 crore in Q1 FY26, while the EBITDA margin contracted to 16.7% from 25.6% a year earlier.
On the business front, the India business remained the key growth driver, with revenue rising 12% year-on-year to Rs 3,452 crore. Revenue from One Africa- comprising South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access - also grew 12% to Rs 977 crore, while Emerging Markets and Europe recorded 16% growth to Rs 999 crore.
However, revenue from North America declined 21% year-on-year to Rs 1,532 crore, while the API and other business segment fell 28% to Rs 160 crore during the quarter.
During the quarter, research and development (R&D) expenditure increased 12.3% year-on-year to Rs 486 crore, accounting for 6.8% of sales, driven by higher product filings and ongoing development initiatives.
Achin Gupta MD and Global CEO, Cipla, said, “We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of Rs 7,119 crore. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of Consumer Health Business maintained leadership position.
The US business posted a revenue of $162 million during the quarter. We expect continued sequential growth in North America, supported by upcoming product pipeline. South Africa private business continued to grow faster than the market. Emerging Markets and Europe continued its growth trajectory with revenue growth of 5% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.”
Transition of Ashish Adukia, Global Chief Financial Officer, to internal business leadership role. Consequent to such transition, Ashish Adukia has relinquished the position as the Global Chief Financial Officer and Key Managerial Personnel (KMP) of the Company with effect from close of business hours of 23 July 2026.
Appointment of Dinesh Jain, Chief – Corporate Finance, as Global Chief Financial Officer and KMP with effect from 24 July 2026.
Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT).
The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.